• Bioresorbable vascular scaffolds (BVS) have emerged as an alternative to conventional metallic DES for the treatment of coronary artery disease.
• Currently, BVS use is expanding from simple to more complex lesions such as bifurcations, calcific lesions, diffuse disease, thrombus-containing lesions, ISR and CTO, despite technical challenges associated with their implantation.
• Of note, clinical outcomes after treatment with BVS for complex coronary lesions have yet to be fully clarified.

CONCLUSION

• GHOST-EU represents one of the largest real-world cohorts of bifurcations treated with BVS
• Provisional approach was default strategy (86%)
• Cross-over from provisional to double-stenting in 4%
• Elective double stenting only in 14%
• BVS in bifurcations is associated with acceptable rates of MACE, TVF & TLR
• Stent thrombosis rate of 2.5% at 12-months is concerning and is most probably related to learning curve and suboptimal technique